Advertisement
Advertisement
ALDX
Aldeyra Therapeutics, Inc.
1.73
USDSponsored
0.00
0.00%
May 08, 15:59 UTC -4
Closed
After-Market
1.75
+0.02
+0.87%
ALDX Earnings Reports
Positive Surprise Ratio
ALDX beat 25 of 42 last estimates.
60%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.13
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
--
/--
Aldeyra Therapeutics, Inc. earnings per share and revenue
On Feb 27, 2026, ALDX reported earnings of -0.13 USD per share (EPS) for Q3 25, beating the estimate of -0.24 USD, resulting in a 47.98% surprise. Revenue reached --, compared to an expected 24.73 million, with a -100.00% difference. The market reacted with a +2.93% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.13 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+296.08%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
May 07, 2026 For Q1 26
Estimate
$0.24
Actual
$0.24
Surprise
-1.96%
SIGA Technologies Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Profound Medical Corp. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+25.75%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
ZOETIS INC.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.63
Actual
$1.53
Surprise
-6.19%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
NewAmsterdam Pharma Company N.V. Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.40
Surprise
+20.32%
FAQ
What were Aldeyra Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Aldeyra Therapeutics, Inc. reported EPS of -$0.13, beating estimates by 47.98%, and revenue of $0.00, -100% below expectations.
How did the market react to Aldeyra Therapeutics, Inc.'s Q3 2025 earnings?
The stock price moved up 2.93%, changed from $5.46 before the earnings release to $5.62 the day after.
When is Aldeyra Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Aldeyra Therapeutics, Inc.'s next earnings report?
Based on 4
analysts, Aldeyra Therapeutics, Inc. is expected to report EPS of -$0.13 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement